Skip to main content
. 2024 Sep 12;9(12):3553–3569. doi: 10.1016/j.ekir.2024.09.004

Table 3.

Summary of the included grey literature

Characteristics of grey literature reports included Total n (%) Recommended with conditions (n = 48) Not recommended (n = 17) Inconclusive evidencea (n = 6)
Country of studyb (N = 72)
 UK 32 (44) 25 4 3
 AU 15 (21) 9 5 0
 Canada 20 (28) 12 8 0
 Other 5 (7) 2 0 3
Intervention studiedb (N = 72)
Renal cell carcinoma
 Avelumab-with-axitinib 2 (3) 1 1 0
 Axitinib 2 (3) 2 0 0
 Cabozantinib based strategiesc 5 (7) 5 0 0
 Lenvatinib based strategiesd 4 (6) 3 1 0
 Nivolumab based strategiese 4 (6) 4 0 0
 Pembrolizumab based strategiesf 5 (7) 4 1 0
 Sorafenib 2 (3) 1 1 0
 Sunitinib 2 (3) 1 1 0
 Otherg 5 (7) 4 1 0
Systemic lupus erythematosus
 Belimumab 3 (4) 1 2 0
 Anifrolumab 2 (3) 1 1 0
Atypical hemolytic uremic syndrome
 Eculizumab 2 (3) 1 1 0
 Ravulizumab 4 (6) 4 0 0
Autosomal dominant polycystic kidney disease
 Tolvaptan 3 (4) 2 1 0
Fabry disease
 Agalsidase alfa 1 (1) 0 1 0
 Migalastat 3 (4) 3 0 0
 Pegunigalsidase 1 (1) 1 0 0
 Enzyme replacement therapies 1 (1) 0 0 1
Other diseases studiedh 21 (29) 12 4 5
a

Includes 1 cost of illness study identified in the grey literature.

b

Multiple interventions and countries covered in some studies.

c

Including cabozantinib and cabozantinib plus nivolumab.

d

Including lenvatinib, lenvatinib plus everolimus, and Lenvatinib plus pembrolizumab.

e

Including nivolumab and nivolumab-with-ipilimumab.

f

Including pembrolizumab, pembrolizumab plus axitinib, and pembrolizumab plus lenvatinib.

g

Including tivozanib, vinflunine, pazopanib, everolimus and bevacizumab (first line), sorafenib (first- and second line), sunitinib (second-line) and temsirolimus (first-line).

h

Including daratumumab for AL amyloidosis, C3 glomerulopathy, selumetinib for neurofibromatosis type 1, caplacizumab for acquired thrombotic thrombocytopenic purpura, screening programs for genetic diseases, enzyme replacement therapy for lysosmal storage diseases, enzyme replacement therapies for mucopolysaccharidosis type 1, rituximab for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ciclosporin for idiopathic steroid-resistant nephrotic syndrome, cost-of-illness of tuberous sclerosis complex, and burosumab for X-linked hypophosphatemia.